Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1 ‐mutated acute myeloid leukaemia

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

(2020) Courtney D. DiNardo et al.   BLOOD

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

(2020) Robert P. Hasserjian et al.   BLOOD

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease

(2020) Alex Bataller et al.   BRITISH JOURNAL OF HAEMATOLOGY

NPM1 Biology in Myeloid Neoplasia

(2020) Sanjay S. Patel et al.   Current Hematologic Malignancy Reports

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

(2019) Musa Yilmaz et al.   Blood Cancer Journal

NGS‐Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse

(2019) Richard D. Press et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clonal hematopoiesis and preleukemia—Genetics, biology, and clinical implications

(2019) Luise Hartmann et al.   GENES CHROMOSOMES & CANCER

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

(2019) Adriano Venditti et al.   BLOOD

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

(2019) Federico Lussana et al.   Cancers

Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing

(2019) Lauren L. Ritterhouse et al.   Molecular Diagnosis & Therapy

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1 -Mutated AML

(2018) Yi Zhou et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

(2018) Mithun Vinod Shah et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

(2018) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia

(2018) Chi Young Ok et al.   HAEMATOLOGICA

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML

(2018) Erik Delsing Malmberg et al.   LEUKEMIA & LYMPHOMA

Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation

(2018) Juliane Grimm et al.   BONE MARROW TRANSPLANTATION

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 -internal tandem duplication genotypes

(2018) Prajwal C. Boddu et al.   CANCER

Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1

(2018) Yi Zhou et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Maftools: efficient and comprehensive analysis of somatic variants in cancer

(2018) Anand Mayakonda et al.   GENOME RESEARCH

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives

(2018) Fabio Forghieri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

(2018) Nikhil Patkar et al.   Oncotarget

Minimal residual disease in acute myelogenous leukemia

(2017) N. M. Cruz et al.   International Journal of Laboratory Hematology

Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia

(2016) Juan Ouyang et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists

(2016) Zhenya Tang et al.   Molecular Cytogenetics

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

(2015) D. P. Steensma et al.   BLOOD

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

(2015) Houria Debarri et al.   Oncotarget

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

(2014) J M Jaso et al.   BONE MARROW TRANSPLANTATION

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

(2014) Sanam Loghavi et al.   Journal of Hematology & Oncology

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

(2014) M G Della Porta et al.   LEUKEMIA

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

MutatedNPM1in patients with acute myeloid leukemia in remission and relapse

(2013) Preetesh Jain et al.   LEUKEMIA & LYMPHOMA

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

(2012) T M Westers et al.   LEUKEMIA

Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia

(2012) Guilin Tang et al.   LEUKEMIA RESEARCH

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients

(2012) Mikako Warren et al.   MODERN PATHOLOGY

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD